Efetividade do guaraná (Paullinia cupana) para manejo da fadiga em mulheres com câncer de mama em quimioterapia: um ensaio clínico, duplo cego, randomizado

• Ano de defesa: 2017
• Autor(a) principal: Albarnaz, Marcela Dias
• Orientador(a): Bachion, Maria Márcia
• Banca de defesa: Bachion, Maria Márcia, Freitas Junior, Ruffo de, Malaquias, Suelen Gomes
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Goiás
• Programa de Pós-Graduação: Programa de Pós-graduação em Enfermagem (FEN)
• Departamento: Faculdade de Enfermagem - FEN (RG)
• País: Brasil
• Palavras-chave em Português: Oncologia; Câncer de mama; Fadiga; Guaraná; Enfermagem
• Palavras-chave em Inglês: Oncology; Breast cancer; Fatigue; Guarana; Nursing
• Área do conhecimento CNPq: CIENCIAS DA SAUDE::ENFERMAGEM
• Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tede/7208

Fatigue, a symptom of hard treatment due to its multi-dimensionality and multifactoriality, is frequently reported by women with breast cancer undergoing chemotherapy. Researches indicate that guaraná (Paullinia cupana) is a promising intervention for the control of the symptom, but the results still do not show themselves consistent. OBJECTIVE: Assess the effectiveness of 50 mg of guaraná (Paullinia cupana), received twice a day by mouth, for the treatment of fatigue in women with breast cancer under chemotherapy. METHOD: It consists of a randomized clinical trial, double-blind, phase II, placebo controlled. Fatigued women undergoing chemotherapy as the only therapy for the cancer control were randomized in two groups: guarana group (GG) and placebo group (PC). For both groups, an educative program has been conducted in order to uniform the information regarding fatigue. The patients were evaluated in three moments: baseline, 45 and 90 days after the first evaluation. Fatigue was evaluated through the Piper Fatigue Scale- Revised. The analysis of the effectiveness of the intervention and the response rate were adjusted according to age, education level, overweight, medical diagnosis, chemotherapy type, comorbidity, anxiety, depression, alterations on sleep patterns, pain and treatment. RESULTS: 42 women were distributed among the GG (n=21) and PG (n=21) groups. We observed homogeneity in regards to socio-demographic clinical profiles. The inner-group evaluation revealed significant reduction on fatigue scores in GG group, on both total score and behavioral, affective and sensory/cognitive dimensions. The same was not observed on the GP group. The intergroup evaluation revealed a significant statistic difference between the two groups for total scores and behavioral, affective and sensory/cognitive dimensions at the 90th day. A multivariate analyses revealed a reduction of the fatigue rate in 63% (RRA: 0,37; CI 95%: 0,16-0,82) in the GC group. The results of η² revealed a moderate effect on the global fatigue treatment (η² = 0,22), behavioral (η² = 0,13), affective (η² = 0,22) and sensory/cognitive dimensions (η² = 0,16). CONCLUSION: The guarana has shown itself effective in the treatment of fatigue in women with breast cancer undergoing chemotherapy, after 90 days of treatment. The positive effect of the intervention has been observed in both the global fatigue score and in all dimensions evaluated (behavioral, affective and sensory/cognitive).